Status of the Current Treatment Options and Potential Future Targets in Uterine Leiomyosarcoma: A Review

Asano, Hiroshi; Isoe, Toshiyuki; Ito, Yoichi M.; Nishimoto, Naoki; Watanabe, Yudai; Yokoshiki, Saki; Watari, Hidemichi

Status of the Current Treatment Options and Potential Future Targets in Uterine Leiomyosarcoma: A Review

Asano, Hiroshi; Isoe, Toshiyuki; Ito, Yoichi M. et al.

Cancers, 2022, 14(5), 1180

Permalink : https://hdl.handle.net/2115/85521

このアイテムのアクセス数:365件（2026-08-14 10:37 集計）

閲覧可能ファイル

ファイル	フォーマット	サイズ	閲覧回数	説明
https://doi.org/10.3390/cancers14051180			22

論文情報

ファイル出力 EndNote Basic出力 Mendeley出力

アクセス権	open access
URI	https://hdl.handle.net/2115/85521
タイトル	Status of the Current Treatment Options and Potential Future Targets in Uterine Leiomyosarcoma: A Review
著者	Asano, Hiroshi ; Isoe, Toshiyuki ; Ito, Yoichi M. ; Nishimoto, Naoki ; Watanabe, Yudai ; Yokoshiki, Saki ; Watari, Hidemichi
著者名 Asano, Hiroshi
著者名 Isoe, Toshiyuki
著者名 Ito, Yoichi M.
e-Rad_Researcher 90599630 著者名 Nishimoto, Naoki
著者名 Watanabe, Yudai
著者名 Yokoshiki, Saki
e-Rad_Researcher 10344508 著者名 Watari, Hidemichi
言語	英語
キーワード	uterine leiomyosarcoma
	next-generation sequencing
	genomic
	molecular-targeted drugs
	HRD
	BRCA
	PARP inhibitors
発行日	2022-03
出版者	MDPI
収録物名	Cancers
巻(号)	14(5)
ページ	1180
抄録	Simple Summary Uterine leiomyosarcoma (uLMS) is a rare and aggressive mesenchymal malignancy. Although approximately 65% of patients are diagnosed in stage I, more than 50% have relapsed disease, and effective therapies for recurrent and advanced cases are limited. This review summarizes the current standard therapies for uLMS and the molecular properties of uLMS and describes the status of promising novel molecular-targeted therapies. Uterine leiomyosarcoma (uLMS) is the most common subtype of mesenchymal tumors in the uterus. This review aims to summarize the current standard therapies and the molecular properties of uLMS for novel molecular-targeted therapies. Although 65% of uLMS cases are diagnosed in stage I, the 5-year overall survival rate is less than 60%. The only effective treatment for uLMS is complete and early resection, and chemotherapy is the main treatment for unresectable advanced or recurrent cases. No chemotherapy regimen has surpassed doxorubicin monotherapy as the first-line chemotherapy for unresectable advanced or recurrent cases in terms of overall survival in phase 3 trials. As a second-line treatment, pazopanib, trabectedin, and eribulin are used, but their therapeutic effects are not sufficient, highlighting the urgent need for development of novel treatments. Recent developments in gene analysis have revealed that homologous recombination deficiency (HRD), including breast cancer susceptibility gene 2 (BRCA2) mutations, are frequently observed in uLMS. In preclinical studies and several case series, poly(adenosine diphosphate-ribose)polymerase inhibitors showed antitumor effects on uLMS cell lines with BRCA2 mutations or HRD and in recurrent or persistent cases of uLMS with BRCA2 mutations. Thus, HRD, including BRCA mutations, may be the most promising therapeutic target for uLMS.
資源タイプ	学術雑誌論文
出版タイプ	Version of Record
関連情報 (isIdenticalTo)	出版社版DOI https://doi.org/10.3390/cancers14051180